These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31782943)

  • 1. Developments in anticancer vaccination: budding new adjuvants.
    Santos-Sierra S
    Biol Chem; 2020 Mar; 401(4):435-446. PubMed ID: 31782943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.
    Fernández A; Oliver L; Alvarez R; Fernández LE; Lee KP; Mesa C
    Hum Vaccin Immunother; 2014; 10(11):3251-60. PubMed ID: 25483674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
    Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
    Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE
    Immunotherapy; 2013 May; 5(5):497-511. PubMed ID: 23638745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses.
    Garaude J; Kent A; van Rooijen N; Blander JM
    Sci Transl Med; 2012 Feb; 4(120):120ra16. PubMed ID: 22323829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
    Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
    J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
    Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.
    Saxena M; Bhardwaj N
    Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immunostimulatory activity of in silico discovered agonists of Toll-like receptor 2 (TLR2).
    Murgueitio MS; Ebner S; Hörtnagl P; Rakers C; Bruckner R; Henneke P; Wolber G; Santos-Sierra S
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2680-2689. PubMed ID: 28734965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
    Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
    Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
    Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
    J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists.
    Welters MJ; Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; Offringa R; van der Burg SH
    Vaccine; 2007 Feb; 25(8):1379-89. PubMed ID: 17123670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR Agonists as Adjuvants for Cancer Vaccines.
    Li JK; Balic JJ; Yu L; Jenkins B
    Adv Exp Med Biol; 2017; 1024():195-212. PubMed ID: 28921471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses.
    Julier Z; de Titta A; Grimm AJ; Simeoni E; Swartz MA; Hubbell JA
    Vaccine; 2016 May; 34(21):2453-2459. PubMed ID: 27016652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo cancer vaccination: Which dendritic cells to target and how?
    Chiang CL; Kandalaft LE
    Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.